cutaneous squamous cell carcinoma

San Diego, California, USA, August 8, 2026 Neurocrine Biosciences, Inc. has initiated a Phase 1 first-in-human clinical study evaluating...

Toronto, Ontario, Canada, August 8, 2026 Regeneron Canada Company announced that Health Canada has approved Libtayo® (cemiplimab for injection)...

JERUSALEM, July 15, 2026 Alpha Tau Medical announced the successful treatment of the first patient in its ADMIRE clinical...

KING OF PRUSSIA, Pa., May 12, 2026 Phio Pharmaceuticals announced that company leadership will participate in a virtual fireside...

JERUSALEM, May 8, 2026 Alpha Tau Medical Ltd. announced the completion of patient enrollment in its ReSTART pivotal clinical...